TORONTO, March 5, 2025 /PRNewswire/ -- Recently, Visionary announced externally that it has reached a financing consent letter worth $1 billion with the Alfardan Group of Qatar. This financing will be used for the product research and development and global market development of PEGASUS new energy vehicles under Visionary. Although due to confidentiality and the information disclosure requirements of NASDAQ-listed companies, some financing details have not been fully disclosed for the time being, this cooperation will inject strong impetus into the company's development, especially for the new energy vehicle project, and the injection of new funds is of great significance.

-Dordaviprone addresses a significant unmet patient need for patients with rare, high-grade brain tumors- -Transaction to add near-term commercial opportunity to Jazz's pipeline-  -Transaction represents total cash consideration of approximately $935 million, or $8.55 per share- DUBLIN and DURHAM, N.C., March 5, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) ("Jazz" or the "Company") and Chimerix (Nasdaq: CMRX) ("Chimerix"), today announced the companies have entered into a definitive agreement for Jazz to acquire Chimerix for $8.55 per share in cash, representing a total consideration of approximately $935 million. The transaction has been approved by both companies and is expected to close ...

TORRANCE, Calif., March 5, 2025 /PRNewswire/ -- CarParts.com (NASDAQ: PRTS), a leading eCommerce destination for automotive parts and accessories, today announced that it is engaged in a process to explore strategic alternatives to maximize shareholder value, including a possible sale of the company, in response to inbound strategic inquiries the company has received. To support this process, CarParts.com's Board of Directors has engaged Craig-Hallum Capital Group LLC as its financial advisor and Wilson Sonsini Goodrich & Rosati, Professional Corporation as its legal counsel.

PESG Research releases a new market update on Silexion Therapeutics (NASDAQ: SLXN). Silexion recently announced the completion of its initial study evaluating SIL-204 in orthotopic pancreatic cancer models, a critical milestone that could continue to position its next-generation RNAi therapy at the forefront of KRAS-driven cancer treatment. With data analysis now underway and initial results expected in the coming weeks, according to the company’s latest announcement, anticipation seems high for what could be a pivotal breakthrough, if indeed the data is positive.